Preclinical Modeling of Osimertinib for NSCLC With EGFRExon 20 Insertion Mutations
- Resource Type
- Article
- Authors
- Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog
- Source
- Journal of Thoracic Oncology; September 2019, Vol. 14 Issue: 9 p1556-1566, 11p
- Subject
- Language
- ISSN
- 15560864; 15561380
NSCLC with EGFRexon 20 insertion mutations is the third most common type of EGFR-mutant NSCLC and is resistant to EGFR tyrosine kinase inhibitors (TKIs). This study was conducted to evaluate the efficacies of first- to third-generation EGFR TKIs against NSCLC cells harboring EGFRexon 20 insertion mutations.